SMARCA4 and neoplasm: Matsubara et al. [19] showed that SMARCA4 deletion is more involved in the progression of EGFR wild-type lung cancer but not EGFR-mutant tumors, and it was hypothesized that the coexistence of EGFR mutation and SMARCA4 deletion is not suitable for the survival of tumor cells.